H. pylori Eradication Drug Achieves 90%+ Success Rate in Fatty Liver Patients

Treating a stomach infection when the liver is already under stress is a genuine clinical dilemma. Patients with metabolic associated fatty liver disease, or MAFLD, are a growing part of every gastroenterology practice, and a significant number of them also carry H. pylori, the bacterium behind most peptic ulcers and a recognized driver of gastric cancer. Until now, clinicians had little data on whether aggressive antibiotic regimens were safe to use in this overlapping population. A new study published in Frontiers in Pharmacology from researchers at Beijing Jishuitan Hospital offers a reassuring, if preliminary, answer.

Vonoprazan and Amoxicillin Eradicate H. pylori at Over 89% in All MAFLD Severity Groups

The study enrolled 91 patients who had both confirmed H. pylori infection and MAFLD, divided into mild (40 patients), moderate (28), and severe (23) fatty liver groups based on liver stiffness scores from transient elastography using a FibroTouch device. All patients received the same 14-day high-dose dual therapy (HDDT): vonoprazan fumarate at 20 mg twice daily, paired with amoxicillin at 1.0 g three times daily. Vonoprazan is a potassium-competitive acid blocker that suppresses stomach acid more consistently than older proton pump inhibitors, making it a better partner for amoxicillin in this type of regimen.

On an intention-to-treat basis, eradication rates came in at 92.50% for the mild group, 89.29% for moderate, and 91.30% for severe. None of those differences were statistically significant, meaning fatty liver severity did not appear to undermine the treatment's effectiveness. These numbers sit well above the 90% threshold that clinicians generally consider the minimum for an acceptable eradication strategy, and they compare favorably to the 51-52% rates seen in some European HDDT studies, pointing to meaningful regional variation in outcomes.

This matters partly because H. pylori and MAFLD are not unrelated conditions. A 2026 NHANES III follow-up study found that H. pylori seropositivity is independently linked to higher MAFLD prevalence and increased all-cause mortality in community-dwelling adults, suggesting the two conditions may interact in ways that make treating both a clinical priority.

Why Liver Safety in MAFLD Patients Changes the Calculus

MAFLD is not a rare edge case. According to a global burden analysis, metabolic fatty liver disease affects an estimated 1.27 billion people worldwide, making it the most prevalent chronic liver condition on earth. Many of those patients already have elevated liver enzymes at baseline, which makes physicians cautious about adding any drug with hepatotoxic potential.

In this study, baseline alanine aminotransferase (ALT) levels tracked predictably with disease severity: patients with mild fatty liver averaged 29.95 U/L, while those with severe MAFLD averaged 49.63 U/L, a statistically significant difference. After 14 days of HDDT, changes in ALT, AST, GGT, and ALP across all three groups were non-significant. Only two patients, representing 2.2% of the cohort, experienced transient mild transaminase elevations, defined as less than twice the upper limit of normal, and both resolved without intervention. No patient developed grade 2 or higher drug-induced liver injury. That clean safety record across the full spectrum of MAFLD severity is the headline finding here.

Research also suggests that persistent H. pylori infection elevates the risk of developing metabolic steatotic liver disease, adding another reason to prioritize eradication in this population rather than defer it out of hepatic caution.

How the Study Was Designed to Capture Real-World Liver Risk

The research team at the Department of Gastroenterology, Beijing Jishuitan Hospital, Capital Medical University ran the study from October 2024 to December 2025. Stratifying patients by FibroTouch-assessed fatty liver severity was a deliberate methodological choice: it allowed the researchers to test whether the most compromised livers responded differently to HDDT, both in terms of tolerability and eradication success.

The primary outcome tracked liver function markers before and after treatment. Secondary outcomes covered H. pylori eradication rates and adverse reaction incidence. The choice of vonoprazan over a conventional proton pump inhibitor also aligns with the direction recent guidelines are moving: the 2024 ACG guidelines for H. pylori treatment now include vonoprazan dual therapy among recommended alternatives, particularly given rising resistance to clarithromycin-based regimens.

The total adverse reaction rate was 23.08%, with bloating and nausea the most common complaints. No serious adverse events occurred. HDDT's simpler two-drug structure may also be relevant here: compared to bismuth quadruple therapy, it is thought to have a lighter impact on gut microbiota diversity, though that comparison was not directly tested in this study.

Open Questions About Antibiotic Resistance and Sample Size

This study has real limitations worth stating clearly. The cohort is small at 91 patients, all drawn from a single center in Beijing, which limits how confidently its findings can be generalized to other populations. The authors also advise ongoing monitoring of liver function after treatment, acknowledging that the 14-day window captured in this study may not reflect longer-term hepatic changes in the most severe MAFLD cases.

Then there is the antibiotic resistance question. Increasing resistance to clarithromycin and levofloxacin is already undermining H. pylori eradication globally, and while HDDT sidesteps clarithromycin entirely by relying on amoxicillin, resistance patterns for amoxicillin in local H. pylori strains were not reported here. The notably lower HDDT efficacy seen in some European populations compared to the Chinese cohort in this study suggests that regional resistance profiles could significantly shift outcomes.

Next Steps for HDDT in Metabolic Liver Disease

The Beijing Jishuitan findings add meaningful data to a relatively thin evidence base for managing H. pylori in patients with concurrent liver disease. The combination of consistently high eradication rates, no grade 2 or higher liver injury, and a manageable side-effect profile positions HDDT as a viable first-line option in this population, at least in clinical settings where amoxicillin resistance remains low.

For clinicians, the practical takeaway is cautious but real: MAFLD severity, even at the severe end of the spectrum assessed here, did not appear to contraindicate or meaningfully complicate a 14-day vonoprazan-amoxicillin course. Larger, multicenter trials with longer follow-up and local resistance data will be needed before this can be treated as a firm recommendation rather than encouraging preliminary evidence.

Evidence rating

EMERGING — 76/100

Caveats:

• Single-center observational study (n=91); results may not generalize beyond the study population.
• No control group or randomization — this design shows association and clinical safety signals, not causal proof.
• Funding source was not disclosed by the authors.
• Short follow-up period; longer-term hepatic effects were not assessed.
• Not yet independently replicated in an external cohort.

Single-center observational cohort study (n=91) stratified by fatty liver severity. The study reports safety and eradication outcomes before and after treatment but lacks a control group, so it can demonstrate clinical patterns rather than establish causation. Not yet replicated in an independent population.